A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
This is a prospective, open-label, single-arm, non-randomized, multi-center, phase II proof
of concept (PoC) study with a two-stage design and Bayesian interim monitoring to evaluate
efficacy and safety of single agent TKI258 in adult patients with scirrhous gastric carcinoma
(SGC) that have progressed after one or two prior systemic treatments.